Enterprise Value

1.319B

Cash

341.6M

Avg Qtr Burn

-17.56M

Short % of Float

8.41%

Insider Ownership

1.75%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Rusfertide (PTG-300) (Hepcidin Mimetic) Details
Blood cancer, Polycythemia vera, Cancer

Phase 3

Update

Phase 2b

Initiation

Rusfertide (PTG-300) (Hepcidin Mimetic) Details
Genetic disorder, Rare genetic disease

Failed

Discontinued

PTG-200 (IL-23R Antagonist) Details
Crohns disease, Inflammatory bowel disease, Inflammatory disease

Failed

Discontinued

PN-943 (α4β7-Integrin Antagonist) Details
Inflammatory bowel disease, Inflammatory disease

Failed

Discontinued